- Home
- FBRX vs BUR Comparison
FBRX vs BUR Comparison
Compare FBRX & BUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | BUR |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.4M | 1.0B |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FBRX | BUR |
|---|---|---|
| Price | $76.89 | $4.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $67.00 | $13.58 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | ★ 61.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $36,000.00 | ★ $413,360,000.00 |
| Revenue This Year | N/A | $104.62 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.18 | $3.59 |
| 52 Week High | $77.20 | $14.14 |
Technical Indicators
Market Signals| Indicator | FBRX | BUR |
|---|---|---|
| Relative Strength Index (RSI) | 84.38 | 49.21 |
| Support Level | $26.85 | $4.19 |
| Resistance Level | $77.20 | $4.54 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -1.75 | -0.00 |
| Stochastic Oscillator | 88.64 | 56.30 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About BUR Burford Capital Limited
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.